WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9, 2023 and February 29, 2024, both dates inclusive (the "Class Period"), of the important August 6, 2024 lead plaintiff deadline. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of thes ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Gritstone To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $25,000 investing in Gritstone stock or options between March 9, 2023 and February 29, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www ...

Core Viewpoint - Gritstone bio, Inc. is facing allegations of issuing materially false and misleading statements regarding its COVID-19 vaccine development and funding capabilities, which has led to a class action lawsuit by shareholders [2]. Group 1: Allegations and Impact - The complaint alleges that Gritstone would be unable to launch the Phase 2b CORAL Study for its approved COVID-19 vaccine within the timeframe communicated to investors [2]. - This inability to launch the study is expected to impair Gritstone's ability to secure external funding, negatively affecting its balance sheet and cash position [2]. - Consequently, Gritstone is accused of overstating its capability to successfully develop and commercialize its products, rendering its public statements materially false and misleading [2]. Group 2: Class Action Details - The class period for the lawsuit is defined as March 9, 2023, to February 29, 2024, and shareholders are encouraged to register for participation [1]. - The deadline for shareholders to seek lead plaintiff status is August 6, 2024, and there is no cost or obligation to participate in the case [3]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Group 1 - The article discusses a class action lawsuit against Gritstone bio, Inc. for alleged violations of the Securities Exchange Act of 1934 [5][6] - The lawsuit claims that Gritstone issued false and misleading statements and failed to disclose important information to investors [2] - The class period for the lawsuit is defined as March 9, 2023, to February 29, 2024 [6] Group 2 - UiPath's CEO Rob Enslin announced his resignation effective June 1, 2024, to be replaced by former CEO Daniel Dines, leading to a 34% drop in shares the following day [2] - The article highlights the importance of contacting DJS Law Group for shareholders who purchased shares during the class period for potential lead plaintiff appointments [1][4]

Core Insights - Gritstone bio, Inc. is hosting a virtual key opinion leader event on August 2, 2024, focusing on the treatment landscape for metastatic microsatellite stable colorectal cancer (MSS-CRC) [1] - The event will feature Dr. J. Randolph Hecht and Howard Brown, who will discuss the unmet needs in MSS-CRC treatment [1] - Gritstone is advancing its personalized neoantigen vaccine program, GRANITE, targeting immunologically "cold" tumors like MSS-CRC, with mature progression-free survival data expected in Q3 2024 [2] Company Overview - Gritstone bio, Inc. is a clinical-stage biotechnology company focused on developing potent vaccines to improve patient outcomes and eliminate diseases [6] - The company utilizes innovative vectors and payloads to engage multiple arms of the immune system against critical disease targets [6]

Shareholders who purchased shares of GRTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: March 9, 2023 to February 29, 2024 CONTACT US HERE: DEADLINE: August 6, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/gritstone-loss-submission-form/?id=91383&from=3 WH ...

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- SO WHAT: If you purchased Gritstone securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigat ...

Core Points - The Gross Law Firm has issued a notice to shareholders of Gritstone bio, Inc. regarding a class action lawsuit [1] - The class period for the lawsuit is from March 9, 2023, to February 29, 2024 [3] - Shareholders are encouraged to register for monitoring and updates related to the case, with a deadline to seek lead plaintiff status by August 6, 2024 [3][5] Allegations - The complaint alleges that Gritstone bio made materially false and misleading statements regarding its ability to launch the Phase 2b CORAL Study for its COVID-19 vaccine [6] - It is claimed that the company would be unable to launch the study within the timeframe previously communicated to investors [6] - The inability to launch the study is said to impair Gritstone's ability to secure external funding, negatively affecting its financial position [6] - The allegations suggest that Gritstone overstated its capability to develop and commercialize its products, leading to misleading public statements [6]

NEW YORK, July 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ: GRTS). Shareholders who purchased shares of GRTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/gritstone-loss-submission-form/?id=90339&from=4 CLASS PERIOD: March 9, 2023 to Feb ...

NEW YORK, July 10, 2024 /PRNewswire/ -- So what: If you purchased Gritstone securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Gritstone would be unable to launch the Phase 2b CORAL Study, a study comparing Gritstone's COVID-19 vaccine candidate with an approved COVID ...